abilify- aripiprazole tablet abilify- aripiprazole solution abilify- aripiprazole tablet, orally disintegrating abilify- arip
otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea
abilify 9.75mg1.3ml solution for injection vials
otsuka pharmaceuticals (u.k. - aripiprazole - solution for injection - 7.5mg/1ml
abilify maintena 400mg powder and solvent for prolonged-release suspension for injection pre-filled syringes
otsuka pharmaceuticals (u.k. - aripiprazole - powder and solvent for suspension for injection - 400mg
abilify maintena aripiprazole (as monohydrate) 400 mg powder and solvent for prolonged release suspension for injection vial
lundbeck australia pty ltd - aripiprazole, quantity: 400 mg (equivalent: aripiprazole monohydrate, qty 416.07 mg) - injection, diluent for - excipient ingredients: water for injections - for the acute and maintenance treatment of schizophrenia in adults. for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in adult patients as monotherapy.
abilify maintena aripiprazole (as monohydrate) 300 mg powder and solvent for prolonged release suspension for injection vial
lundbeck australia pty ltd - aripiprazole, quantity: 300 mg (equivalent: aripiprazole monohydrate, qty 312.05 mg) - injection, diluent for - excipient ingredients: water for injections - for the acute and maintenance treatment of schizophrenia in adults. for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in adult patients as monotherapy.
abilify maintena aripiprazole (as monohydrate) 400 mg powder and solvent for prolonged release suspension for injection pre-filled syringe
lundbeck australia pty ltd - aripiprazole, quantity: 400 mg (equivalent: aripiprazole monohydrate, qty 416.07 mg) - injection, powder for - excipient ingredients: carmellose sodium; mannitol; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - for the acute and maintenance treatment of schizophrenia in adults. for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in adult patients as monotherapy.
abilify maintena aripiprazole (as monohydrate) 300 mg powder and solvent for prolonged release suspension for injection pre-filled syringe
lundbeck australia pty ltd - aripiprazole, quantity: 300 mg (equivalent: aripiprazole monohydrate, qty 312.05 mg) - injection, powder for - excipient ingredients: carmellose sodium; mannitol; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - for the acute and maintenance treatment of schizophrenia in adults. for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in adult patients as monotherapy.
5d injection
claris otsuka private limited survey no. 199 to 201 & 208 to 210, village- - anhydrous glucose bp - injection - 50 g/l - intravenous solutions: solutions for parenteral
dextran 40 (10 %w/v) intr.infusion & glucose 5 % b.p.
otsuka egypt - infusion - 10 %
dextrose 10% & sodium chloride 0.9%
otsuka egypt - injection